BIO:NYE-Bio-Rad Laboratories Inc. Class A (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 328.36

Change

+0.89 (+0.27)%

Market Cap

USD 5.05B

Volume

0.10M

Analyst Target

USD 525.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Bio-Rad Laboratories Inc manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a products and systems used to separate complex chemical and biological materials.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-23 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

+0.08 (+0.07%)

USD 200.50B
MDT Medtronic PLC

+0.37 (+0.46%)

USD 103.90B
ZBH Zimmer Biomet Holdings Inc

-0.30 (-0.28%)

USD 21.51B
STE STERIS plc

+0.51 (+0.25%)

USD 21.31B
GMED Globus Medical

+0.47 (+0.57%)

USD 11.25B
SNN Smith & Nephew SNATS Inc

-0.12 (-0.49%)

USD 10.75B
PEN Penumbra Inc

-1.99 (-0.82%)

USD 9.31B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 9.16B
GKOS Glaukos Corp

-2.52 (-1.67%)

USD 8.32B
INSP Inspire Medical Systems Inc

-0.19 (-0.10%)

USD 5.63B

ETFs Containing BIO

SYNB Putnam Biorevolution ETF 6.13 % 0.00 %

+0.26 (+1.78%)

USD 5.36M
MHOT:AU VanEck Morningstar Wide M.. 3.01 % 0.00 %

+2.42 (+1.78%)

N/A
GERM 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.69% 61% D- 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.69% 61% D- 31% F
Trailing 12 Months  
Capital Gain 2.38% 65% D 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.38% 65% D 33% F
Trailing 5 Years  
Capital Gain -10.96% 54% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.96% 54% F 20% F
Average Annual (5 Year Horizon)  
Capital Gain -5.53% 29% F 11% F
Dividend Return -5.53% 29% F 8% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 33.34% 58% F 31% F
Risk Adjusted Return -16.59% 29% F 12% F
Market Capitalization 5.05B 74% C 85% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 51.90 N/A N/A
Price/Book Ratio 1.22 77% 63%
Price / Cash Flow Ratio 24.46 30% 14%
Price/Free Cash Flow Ratio -13.07 85% 95%
Management Effectiveness  
Return on Equity -9.79% 42% 21%
Return on Invested Capital 5.57% 67% 48%
Return on Assets 1.86% 52% 45%
Debt to Equity Ratio 13.72% 78% 84%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.